Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases

Clinically meaningful efficacy in the treatment of brain tumors, including melanoma brain metastases (MBM), requires selection of a potent inhibitor against a suitable target, and adequate drug distribution to target sites in the brain. Deregulated constitutive signaling of mitogen-activated protein...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Drug Metab Dispos
Главные авторы: Gampa, Gautham, Kim, Minjee, Cook-Rostie, Nicholas, Laramy, Janice K., Sarkaria, Jann N., Paradiso, Linda, DePalatis, Louis, Elmquist, William F.
Формат: Artigo
Язык:Inglês
Опубликовано: The American Society for Pharmacology and Experimental Therapeutics 2018
Предметы:
Special Section on Transporters in Drug Disposition and Pharmacokinetic Prediction
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896365/
https://ncbi.nlm.nih.gov/pubmed/29437873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.117.079194
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы